CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma
Pedro Rocha(The University of Texas MD Anderson Cancer Center), Luisa M. Solis(The University of Texas MD Anderson Cancer Center)
Cited by 29
Related Papers
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features
|Clinical Cancer Research|2010|422
PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinoma
|Science Translational Medicine|2020|68
Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development
|American Journal of Respiratory and Critical Care Medicine|2020|46
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer
|Journal of Clinical Investigation|2023|29